Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

On World Clubfoot Day join our researchers and surgeons for an exhibition and demonstrations at the Nuffield Orthopaedic Centre (NOC). This Friday 3 June you can help us make a difference for children born with clubfoot worldwide. Around 200,000 children each year are born with clubfoot, with around 80% of these in low and middle-income countries.

Around 200,000 children each year are born with clubfoot, with around 80% of these in low and middle-income countries.

If left untreated, clubfoot becomes a painful and severely disabling deformity, where the feet point down and inwards and with the soles of the feet backwards; however, the simple Ponseti treatment is successful in up to 95% of cases, especially if this is initiated early.

NDORMS Professor Chris Lavy has worked with children with clubfoot for the last 30 years, both in the UK and Africa. He currently leads a project that is strengthening training and delivery capacity for clubfoot treatment in 15 sub-Saharan countries - the Africa Clubfoot Training Project.

Read more (Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science (NDORMS) website)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.